bioMérieux S.A. (BMXMF)

Market Cap	15.98B
Revenue (ttm)	4.84B
Net Income (ttm)	443.81M
Shares Out	n/a
EPS (ttm)	3.72
PE Ratio	36.01
Forward PE	24.07
Dividend	1.02 (0.76%)
Ex-Dividend Date	Jun 9, 2025

Volume	100
Average Volume	17
Open	152.00
Previous Close	135.01
Day's Range	135.01 - 152.00
52-Week Range	100.50 - 152.00
Beta	0.47
RSI	31.33
Earnings Date	Sep 4, 2025

About bioMérieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemase producing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO or 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VI...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1963
• Employees: 14,754
• Stock Exchange: OTCMKTS
• Ticker Symbol: BMXMF

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.

Financial numbers in EUR